Purpose: Lymphocyte subset recovery is an important factor that determines the success of hematopoietic stem cell transplantation (HSCT). Temporal differences in the recovery of lymphocyte subsets and the factors influencing this recovery are important variables that affect a patient's posttransplant immune reconstitution, and therefore require investigation. Methods: The time taken to achieve lymphocyte subset recovery and the factors influencing this recovery were investigated in 59 children who had undergone HSCT at the Department of Pediatrics, The Catholic University of Korea Seoul St. Mary's Hospital, and who had an uneventful follow-up period of at least 1 year. Analyses were carried out at 3 and 12 months post-transplant. An additional study was performed 1 month post-transplant to evaluate natural killer (NK) cell recovery. The impact of preand post-transplant variables, including diagnosis of Epstein-Barr virus (EBV) DNAemia posttransplant, on lymphocyte recovery was evaluated. Conclusion: In our pediatric allogeneic HSCT cohort, helper T cells were the last subset to recover. Younger age and EBV DNAemia had a negative impact on the post-transplant recovery of T cells and B cells.
Introduction
Hematopoietic stem cell transplantation (HSCT) is now widely used for the treat ment of children with blood diseases. An important factor in the prognosis of the patient posttransplant is host immune reconstitution (IR) which, if delayed, may increase the risk of infection, disease recurrence and secondary malignancies after transplant 1) . IR is affected by various treatmentrelated variables, such as the period of antibiotic use, routine administration of intravenous immunoglobulin (IVGV), and immunomodulatory treatment after transplant such as donor lymphocyte infusion. According past literature, IR occurs in the order of monocyte, granulocyte, macro Korean J Pediatr 2013;56(1):26-31 phage, and natural killer (NK) cell, resulting in the restoration of a functional innate immune system. Recovery of the adap tive immune system, however, occurs over a considerably long er period of time, with B cell restoration requiring at least six months, and T cell recovery often taking two years for completion 1) . Factors influencing IR at the time of transplant include pa tient age, donor type, stem cell source, and method of T cell depletion, while prevention and treatment of graftversushost disease (GVHD) are significant factors influencing IR after transplant 2) . According to a recent Korean study on pediatric recipients of allogeneic HSCT, NK cells and cytotoxic T cells were ra pidly restored after HSCT, with 92% and 76% of patients, respectively showing recovery at 3 months posttransplant. However, IR was slower for helper T cells and B cells which showed recovery in 85% and 69% of patients, respectively at 12 months posttransplant 3) . Important results that derive from this study are the negative effects of certain conditioning regimens, including the use of total body irradiation (TBI) and antithymocyte globulin (ATG), cord blood as the cell source, and diagnosis of chronic GVHD, on lymphocyte re constitution. Despite this and other previous reports on IR 4, 5) , studies on IR in pediatric recipients of allogeneic HSCT are few. Also, an important factor which has not yet received full analysis as a possible modulator of IR is posttransplant EpsteinBarr virus (EBV) infection. In this study, we evaluated the recovery of each lymphocyte subset in 59 recipients of allogeneic HSCT at our institution. In addition to the impact of wellestablished variables such as patient age, donor type, acute and chronic GVHD on IR, we also analyzed EBV infection for possible effects on lym phocyte recovery.
Materials and methods

Patient cohort
From January 2009 to December 2010, 90 patients received allogeneic HSCT at the Department of Pediatrics, The Catholic University of Korea Seoul St. Mary's Hospital. Out of this initial cohort, the following exclusions were made: 14 patients who relapsed within 1 year of transplant, 8 patients who died of transplantrelated mortality within 1 year, 2 patients who experienced graft failure, and 7 patients with incomplete records concerning lymphocyte subset recovery. The final study cohort included 59 patients, the major characteristics of whom are summarized in Table 1 .
Transplant method
For infection prophylaxis, oral acyclovir was given from the start of conditioning to day 42, and oral trimethoprim sulfamethoxazole was given from the start of conditioning to day 3, and from neutrophil engraftment to at least 6 months after transplant. Granulocytecolony stimulating factor was given from day 5 to the time when the absolute neutrophil count surpassed 3.0×10 9 /L. For antifungal prophylaxis, we administered intravenous (IV) micafungin (1 mg/kg/day) from the start of conditioning to neutrophil engraftment, followed by oral fluconazole for at least 2 months.
GVHD prophylaxis consisted of IV cyclosporine from day 1 and minidose methotrexate (5 mg/m 2 ) given at days 1, 3, 6, and 11.
After transplant, EBV DNA titers were evaluated at fort nightly inter vals for up till 3 months posttransplant using a realtime quantitative method. Rituximab was administered only with diagnosis of posttransplantation lymphoproliferative disease (PTLD).
Immunophenotypic studies
Bone marrow examination and peripheral blood lymphocyte subset analysis were done at intervals of 1, 3, 6, 9, and 12 months after HSCT.
With + , the antigens of T cell, B cell, and NK cell, were analyzed through fluorescenceactivated cell sorter system, and the absolute values of each subset were calculated using the percentage of each lymphocyte subset and the absolute lymphocyte counts (ALCs).
The normal value of each lymphocyte subset varies ac cording to age 1) . In this study, the normal values for each lym phocyte subset, as outlined in a previously published paper, were used 2) .
Study endpoints
The main study endpoints were as follows; first, we aimed to identify the number of patients with lymphocyte sub set recovery, defined as the 25th percentile of normal val ue. Second, we analyzed for factors that may impact the re covery of each lymphocyte subset, including patient age, donor type, stem cell source, the use of either TBI or ATG in conditioning, diagnosis of acute or chronic GVHD, and EBV DNAemia. For this second analysis, both the 25th and 75th percentile of normal values were used. EBV DNAemia was defined as having a positive value when more than 500 copies were detected per 1 mL by realtime quantitative polymerase chain reaction. All analyses were done for 3 and 12 months post transplant. In addition, analyses for NK cell recovery and risk factors for NK cell recovery were done at 1 month post transplant.
Statistical analysis
Logistic regression analysis was performed to determine whether the pre and posttransplant independent variables had a significant impact on recovery of each lymphocyte sub set. Factors with a P value<0.05 in univariate analysis were entered into a multivariate study. Statistical analysis was done using the SAS ver. 8 (SAS Institute Inc., Cary, NC, USA). The P value was considered significant when <0.05.
Results
Recovery of each lymphocyte subset to normal value
With regards to ALC, 34 patients (57%) in the overall cohort showed recovery at 12 months posttransplant ( 2. Factors influencing the recovery of lymphocyte subset (Table 3) 
1) Total lymphocyte count recovery
The use of ATG in conditioning significantly decreased the percentage of patients with total lymphocyte count recovery (25th percentile reference) at 12 months posttransplant (P= 0.035). However, none of the other factors proved significant at any of the time points evaluated. Data represented as number of patients with subset recovery within specified category/number of patients within specified category. HSCT, hematopoietic stem cell transplantation; 75P, 75th percentile reference; 25P, 25th percentile reference; CD, cluster of differentiation; ALC, absolute lymphocyte count; BM, bone marrow; PB, peripheral blood; TBI, total body irradiation; ATG, anti-thymocyte globulin; aGVHD, acute graft versus host disease; cGVHD, chronic GVHD; EBV, Epstein-Barr virus; NS, not significant.
2) CD16
Discussion
Previous studies have shown that among lymphocyte sub sets, NK cells are the first to recover to normal levels after allogeneic HSCT. The recovery of T cells and B cells is much slower, and amongst T cells, cytotoxic T cells seem to show faster reconstitution than helper T cells 3) . The timing of B cell and T cell recovery has been a matter of controversy, with several previous studies concluding that the B cell recovered faster than the helper T cell, allowing the B cell to stimulate the thymus for T cell maturation and differentiation 1) . The results from our study also support the view that B cell recovery precedes helper T cell recovery, allowing for sequential lymphocyte maturation. Although the NK cell is known to repopulate rapidly, only 47% of the cohort showed normal levels by 1 month since transplant. Factors contributing to delayed early recovery of NK cells were younger patient age, the use of TBI in the conditioning regimen, and previous diagnosis of acute GVHD, with the last factor proving most significant in multivariate study.
Several important points can be made regarding factors that influence the recovery of each lymphocyte subset.
Although patient age has been reported to be an important factor, the age threshold with which the overall cohort has been divided, has varied from 10 to 16 years old 2, 4) . Reports on the impact of patient age have also been conflicting. Some researchers have suggested that lymphocyte recovery occurs much faster in older patients 2) , while others have shown evi dence that recovery is faster in the younger age group 4) . In our study, patients in the younger age group showed a significantly lower likelihood of both cytotoxic T cell and B cell recovery at 12 months posttransplant in multivariate analysis. One hypothesis for this result is that younger children may have less mature lymphoid organs that are more prone to damage from the HSCT conditioning regimen.
Previous reports have shown that, although there is no dif fer ence in recovery of the innate immune system, related and unrelated transplants have shown discrepancies with regards to recovery of antigenspecific cellular immunity 6) . In our study, the effect of donor type in posttransplant IR was not significant in multivariate study, although univariate effects of delayed CD16 + /CD56 + and CD3 + cell recovery were noted.
Past studies have shown a faster rate of CD3 + /CD4 + and CD3 + /CD8 + lymphocyte recovery in recipients of peripheral blood stem cell transplantation, compared to bone marrow transplantation 7) . Our study did not show an advantage for either cell source with regards to IR, consistent with a recent domestic report on immune recovery 3) . The effect of ATG administered as part of the conditioning regimen on IR is a matter of controversy, with at least 1 study concluding that ATG has no significant effect on immu nological recovery 8) . In our study, the use of ATG had a signi ficantly detrimental effect on the recovery of ALC, as evi denced at 1 year posttransplant.
The possible role of GVHD in IR has been studied consi derably, with published data suggesting that acute GVHD and subsequent treatment may delay the recovery of CD3 + / CD4 + lymphocytes 9) . GVHD is known to deter the activities of the thymus, and suppress both CD3 Relatively little is known of the impact of EBV infection on the recovery of specific lymphocyte subsets. Past studies have shown that lymphocyte subset recovery was accelerated with cytomegalovirus infection 5) , and that EBV specific T lymphocytes increased with EBV infection 10) . The entity of PTLD would indicate that B cell lymphocyte proliferation is increased by EBV infection to the extent of gaining malignant potential 1113) , and another study found that early infection by EBV or adenovirus delayed immune reconstruction because such early infections are linked to pathogenesis of chronic GVHD 14) . In our study, we found that EBV infection, as dia results from our pediatric cohort should contribute to a greater understanding of IR after allogeneic HSCT in children, and may provide the basis for larger scale studies of the role of both
